GTHP Pengajuan SEC - Guided Therapeutics, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

924515

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Guided Therapeutics, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 14, 2025	EX-10.6	Form of Warrants dated May 2, 2025 issued to John Gould EXHIBIT 10.6 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
August 14, 2025	EX-10.4	Form of Securities Purchase Agreement dated May 1, 2025 with 1800 Diagonal Lending LLC EXHIBIT 10.4 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of May 1, 2025, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation, with its address at 5835 Peachtree Corners East, Suite B, Peachtree Corners, Georgia 30092 (the “Company”), and 1800 DIAGONAL LENDING LLC, a Virginia limited liability company, with its address at 1800 Diagonal R
August 14, 2025	EX-10.5	Form of $75,000 Promissory Note dated May 2, 2025 issued to John Gould EXHIBIT 10.5 CONVERTIBLE PROMISSORY NOTE Original Issuance Date: May 2, 2025 Principal Amount: $75,000.00 THIS PROMISSORY NOTE is duly authorized and validly Note of Guided Therapeutics, Inc., a Delaware corporation, (the “Company”), having its principal place of business at 5835 Peachtree Corners East, Suite B, Peachtree Corners, Georgia 30092. FOR VALUE RECEIVED, the undersigned promises to pay
August 14, 2025	EX-10.7	Letter from the Compensation Committee of the Board of Directors of Guided Thereaputics, Inc. to Mark Faupel, dated June 3, 2025, approving revised compensation package EXHIBIT 10.7 To: Mark Faupel – Guided Therapeutics, Inc. CEO From: Guided Therapeutics’ Board of Directors Compensation Committee Re: Revised Compensation Package Date: June 3, 2025 Dear Mark: The Guided Therapeutics Compensation Committee has recommended, and its Board of Directors has approved by a unanimous vote held on June 3, 2025, a revised compensation package for you as described below. We
August 14, 2025	EX-10.3	Form of Promissory Note dated May 1, 2025 issued to 1800 Diagonal Lending LLC EXHIBIT 10.3 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN
August 14, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934 For the quarterly period ended June 30, 2025 Commission File No. 000-22179 GUIDED THERAPEUTICS, INC. (Exact Name of Registrant as Specified
August 14, 2025	EX-10.1	Form of Promissory Note dated April 1, 2025 issued to 1800 Diagonal Lending LLC EXHIBIT 10.1 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN
August 14, 2025	EX-10.2	Form of Securities Purchase Agreement dated April 1, 2025 with 1800 Diagonal Lending LLC EXHIBIT 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the "Agreement), dated as of April 1, 2025, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation, with its address at 5835 Peachtree Corners East, Suite B, Peachtree Corners, Georgia 30092 (the "Company"), and 1800 DIAGONAL LENDING LLC, a Virginia limited liability company, with its address at 1800 Diagonal
May 15, 2025	EX-10.5	Form of Promissory Note Dated May 1, 2025 EXHIBIT 10.5 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN
May 15, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934 For the quarterly period ended March 31, 2025 Commission File No. 000-22179 GUIDED THERAPEUTICS, INC. (Exact Name of Registrant as Specified
May 15, 2025	EX-10.1	Form of Convertible Promissory Note Dated May 2, 2025 EXHIBIT 10.1 CONVERTIBLE PROMISSORY NOTE Original Issuance Date: May 2, 2025 Principal Amount: $75,000.00 THIS PROMISSORY NOTE is duly authorized and validly Note of Guided Therapeutics, Inc., a Delaware corporation, (the “Company”), having its principal place of business at 5835 Peachtree Corners East, Suite B, Peachtree Corners, Georgia 30092. FOR VALUE RECEIVED, the undersigned promises to pay
May 15, 2025	EX-10.3	Form of Promissory Note Dated April 1, 2025 EXHIBIT 10.3 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN
May 15, 2025	EX-10.2	Form of Warrant Dated May 2, 2025 EXHIBIT 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
May 15, 2025	EX-10.6	Form of Securities Purchase Agreement Dated May 1, 2025 EXHIBIT 10.6 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of May 1, 2025, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation, with its address at 5835 Peachtree Corners East, Suite B, Peachtree Corners, Georgia 30092 (the “Company”), and 1800 DIAGONAL LENDING LLC, a Virginia limited liability company, with its address at 1800 Diagonal R
May 15, 2025	EX-10.4	Form of Securities Purchase Agreement Dated April 1, 2025 EXHIBIT 10.4 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the "Agreement”), dated as of April 1, 2025, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation, with its address at 5835 Peachtree Corners East, Suite B, Peachtree Corners, Georgia 30092 (the "Company"), and 1800 DIAGONAL LENDING LLC, a Virginia limited liability company, with its address at 1800 Diagonal
March 31, 2025	EX-10.102	Form of Warrant Agreement dated March 18, 2025 EXHIBIT 10.102 EXHIBIT A NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFE
March 31, 2025	EX-10.101	Form of Securities Purchase Agreement dated March 18, 2025 EXHIBIT 10.101 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of 18th of March, 2025 between Guided Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and c
March 31, 2025	EX-10.100	Form of Promissory Note entered into on March 7, 2025 by and between Guided Therapeutics, Inc. and Dr. Mark Faupel EXHIBIT 10.100 PROMISSORY NOTE (Extends long term note payable of the principal of $153,177.69, dated February 18, 2023.) Issuance Date: March 7, 2025 Principal Amount: $153,177.69 THIS PROMISSORY NOTE is duly authorized and validly Note of Guided Therapeutics, Inc., a Delaware corporation, (the “Company”), having its principal place of business at 5835 Peachtree Corners East, Suite B, Peachtree C
March 31, 2025	EX-10.98	Exchange Agreement dated February 28, 2025 by and between Guided Therapeutics, Inc. and Michael C. James EXHIBIT 10.98 EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (this “Agreement”) is made and entered into effective as of the 28 day of February, 2025 by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the “Company”) and the undersigned creditor of the Company (the “Creditor”). W I T N E S S E T H : WHEREAS, the Creditor is an director of the Company and the payee of certain obligations
March 31, 2025	EX-10.99	Form of Exchange Agreements entered into on March 3, 2025 by and between Guided Therapeutics, Inc. and the Series C-1 and C-2 Preferred Stock investors EXHIBIT 10.99 EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (this “Agreement”) is made and entered into effective as of the 3rd day of March 2025, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the “Company”) and the undersigned holder of preferred stock of the Company (the “Holder”). W I T N E S S E T H : WHEREAS, the Company created and issued to certain holders, including the Ho
March 31, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934 Commission File No. 0-22179 GUIDED THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its
March 31, 2025	EX-10.97	Exchange Agreement dated February 28, 2025 by and between Guided Therapeutics, Inc. and Dr. John Imhoff EXHIBIT 10.97 EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (this “Agreement”) is made and entered into effective as of the 28 day of February, 2025 by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the “Company”) and the undersigned creditor of the Company (the “Creditor”). W I T N E S S E T H : WHEREAS, the Creditor is an director of the Company and the payee of certain obligations
December 23, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2024 GUIDED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-22179 58-2029543 (State or other jurisdiction of incorporation) (Commis
December 23, 2024	EX-10.1	Form of Securities Purchase Agreement dated December 18, 2024 EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 18, 2024 between Guided Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and condi
December 23, 2024	EX-4.1	Form of Warrant dated December 18, 2024 EXHIBIT 4.1 EXHIBIT A NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTI
November 14, 2024	EX-10.3	Common Stock Purchase Warrant, dated August 1, 2024 EXHIBIT 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
November 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934 For the quarterly period ended September 30, 2024 Commission File No. 000-22179 GUIDED THERAPEUTICS, INC. (Exact Name of Registrant as Speci
November 14, 2024	EX-10.1	Form of Promissory Note issued to Directors EXHIBIT 10.1 PROMISSORY NOTE Original Issuance Date: , 2024 Principal Amount: THIS PROMISSORY NOTE is duly authorized and validly Note of Guided Therapeutics, Inc., a Delaware corporation, (the “Company”), having its principal place of business at 5835 Peachtree Corners East, Suite B, Peachtree Corners, Georgia 30092. FOR VALUE RECEIVED, the undersigned promises to pay to (“Holder”) the principal
November 14, 2024	EX-10.2	Promissory Note, dated July 23, 2024, in the amount of $50,000 EXHIBIT 10.2 PROMISSORY NOTE $50,000.00 July 23, 2024 FOR VALUE RECEIVED, Guided Therapeutics, Inc., a Delaware corporation (referred to hereinafter as “Maker” and “Company”), hereby promises to pay to Bryan Mamula (“Holder”) the principal sum of Fifty-Thousand Dollars ($50,000.00), plus accrued interest from the date hereof. The principal amount under this Note (“Promissory Note”) shall accrue a
November 14, 2024	EX-10.4	Form of Common Stock Purchase Warrants issued to Directors EXHIBIT 10.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
September 27, 2024	EX-10.1	Form of Securities Purchase Agreement EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 23, 2024 between Guided Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and cond
September 27, 2024	EX-4.1	Form of Warrant EXHIBIT 4.1 EXHIBIT A NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTI
September 27, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2024 GUIDED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-22179 58-2029543 (State or other jurisdiction of incorporation) (Commi
August 14, 2024	EX-10.1	$100,000 Promissory Note Dated June 28, 2024 and Related Common Stock Purchase Warrant EXHIBIT 10.1
August 14, 2024	EX-10.4	$100,050 Promissory Note Dated June 11, 2024 with 1800 Diagonal Lending EXHIBIT 10.4 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN
August 14, 2024	EX-10.7	Securities Purchase Agreement with 1800 Diagonal Lending, dated July 22, 2024 EXHIBIT 10.7 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of July 22, 2024, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation, with its address at 5835 Peachtree Corners East, Suite B, Peachtree Corners, Georgia 30092 (the “Company”), and 1800 DIAGONAL LENDING LLC, a Virginia limited liability company, with its address at 1800 Diagonal
August 14, 2024	EX-10.8	$62,100 Promissory Note Dated July 22, 2024 with 1800 Diagonal Lending EXHIBIT 10.8 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN
August 14, 2024	EX-10.2	Exchange Agreement dated April 15, 2024 EXHIBIT 10.2
August 14, 2024	EX-10.3	Securities Purchase Agreement with 1800 Diagonal Lending EXHIBIT 10.3 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of June 11, 2024, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation, with its address at 5835 Peachtree Corners East, Suite B, Peachtree Corners, Georgia 30092 (the “Company”), and 1800 DIAGONAL LENDING LLC, a Virginia limited liability company, with its address at 1800 Diagonal
August 14, 2024	EX-10.5	$50,000 Promissory Note Dated July 23, 2024 and related Common Stock Purchase Warrant Dated August 1, 2024 EXHIBIT 10.5 PROMISSORY NOTE $50,000.00 July 23, 2024 FOR VALUE RECEIVED, Guided Therapeutics, Inc., a Delaware corporation (referred to hereinafter as “Maker” and “Company”), hereby promises to pay to Bryan Mamula (“Holder”) the principal sum of Fifty-Thousand Dollars ($50,000.00), plus accrued interest from the date hereof. The principal amount under this Note (“Promissory Note”) shall accrue a
August 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934 For the quarterly period ended June 30, 2024 Commission File No. 000-22179 GUIDED THERAPEUTICS, INC. (Exact Name of Registrant as Specified
August 14, 2024	EX-10.6	Form of Promissory Notes Issued to Directors and Form of Related Common Stock Purchase Warrants EXHIBIT 10.6 PROMISSORY NOTE Original Issuance Date: , 2024 Principal Amount: $25,000.00 THIS PROMISSORY NOTE is duly authorized and validly Note of Guided Therapeutics, Inc., a Delaware corporation, (the “Company”), having its principal place of business at 5835 Peachtree Corners East, Suite B, Peachtree Corners, Georgia 30092. FOR VALUE RECEIVED, the undersigned promises to pay to (“Holder”) the
May 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934 For the quarterly period ended March 31, 2024 Commission File No. 000-22179 GUIDED THERAPEUTICS, INC. (Exact Name of Registrant as Specified
March 28, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934 Commission File No. 0-22179 GUIDED THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its
February 20, 2024	SC 13G/A	GTHP / Guided Therapeutics, Inc. / Rosalind Advisors, Inc. Passive Investment SC 13G/A 1 rosalindgthp13ga19feb.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No: 01) Under the Securities Exchange Act of 1934 Guided Therapeutics, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 40171F501 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to
February 20, 2024	EX-99.A BD-DIR-RESOL	Joint Filing Agreement EX-99.A BD-DIR-RESOL 2 rosalindgthpexa19feb2.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial ownership of shares of Common Stock of Guided Therapeutics, Inc. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Master Fund L.P. By: Name: Mike McD
February 14, 2024	SC 13G/A	GTHP / Guided Therapeutics, Inc. / Auctus Fund Management Llc Passive Investment SC 13G/A 1 gthp13gv2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Guided Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 40171F501 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the app
November 13, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934 For the quarterly period ended September 30, 2023 Commission File No. 000-22179 GUIDED THERAPEUTICS, INC. (Exact Name of Registrant as Speci
August 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934 For the quarterly period ended June 30, 2023 Commission File No. 000-22179 GUIDED THERAPEUTICS, INC. (Exact Name of Registrant as Specified
May 15, 2023	EX-10.2	Form of Amended Promissory Note to Gene Cartwright EXHIBIT 10.2 PROMISSORY NOTE (Extends long term note payable of the principal of $267,085.25, dated February 19, 2021.) Issuance Date: February 18, 2023 Principal Amount: $267,085.25 THIS PROMISSORY NOTE is duly authorized and validly Note of Guided Therapeutics, Inc., a Delaware corporation, (the “Company”), having its principal place of business at 5835 Peachtree Corners East, Suite B, Norcross,
May 15, 2023	EX-10.3	Form of Amended Promissory Note to Mark Faupel EXHIBIT 10.3 PROMISSORY NOTE (Extends long term note payable of the principal of $153,177.69, dated February 19, 2021.) Issuance Date: February 18, 2023 Principal Amount: $153,177.69 THIS PROMISSORY NOTE is duly authorized and validly Note of Guided Therapeutics, Inc., a Delaware corporation, (the “Company”), having its principal place of business at 5835 Peachtree Corners East, Suite B, Norcross,
May 15, 2023	EX-4.1	Form of Common Stock Purchase Warrant Issued to Richard Blumberg EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
May 15, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934 For the quarterly period ended March 31, 2023 Commission File No. 000-22179 GUIDED THERAPEUTICS, INC. (Exact Name of Registrant as Specified
May 15, 2023	EX-10.1	Form of 2023 Warrant Exchange Agreements EXHIBIT 10.1 February 15, 2023 Holder of $0.25 (Twenty-Five Cent) Commission Warrants That Expire prior to July 15, 2023 Re: Exchange Offer of Common Stock Purchase Warrants Dear Holder: Guided Therapeutics, Inc. (the “Company”) is pleased to offer to you the opportunity to exchange all of the Common Stock purchase warrants of the Company issued as Commission Warrants (the “Exchange Warrants”) cur
March 30, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934 Commission File No. 0-22179 GUIDED THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its
March 9, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 (March 3, 2023) GUIDED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-22179 58-2029543 (State or other jurisdiction of incorporatio
February 14, 2023	SC 13G/A	GTHP / Guided Therapeutics, Inc. / Auctus Fund Management Llc Passive Investment SC 13G/A 1 gthpv5.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Guided Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 40171F501 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the approp
January 23, 2023	CORRESP	Guided Therapeutics, Inc. 15835 Peachtree Corners East, Suite B Norcross, Georgia 30092 Guided Therapeutics, Inc. 15835 Peachtree Corners East, Suite B Norcross, Georgia 30092 January 23, 2023 VIA EDGAR Benjamin Richie Division of Corporation Finance Office of Industrial Applications and Services U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549-4561 Re: Guided Therapeutics, Inc. Registration Statement on Form S-1 Filed January 13, 2023 File No. 333-2692
January 13, 2023	S-1	As filed with the Securities and Exchange Commission on January 13, 2023 As filed with the Securities and Exchange Commission on January 13, 2023 Registration No.
January 13, 2023	EX-FILING FEES	Filing Fees EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Guided Therapeutics, Inc.
December 2, 2022	RW	Guided Therapeutics Inc. 5835 Peachtree Corners East, Suite B Norcross, Georgia 30092 RW 1 gthprw.htm RW Guided Therapeutics Inc. 5835 Peachtree Corners East, Suite B Norcross, Georgia 30092 December 2, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Re: Guided Therapeutics Inc. Request for Withdrawal Pursuant to Rule 477 of Registration Statement on Form S-1 (File No. 333-259871) Ladies and Gentleman: Pursua
November 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934 For the quarterly period ended September 30, 2022 Commission File No. 0-22179 GUIDED THERAPEUTICS, INC. (Exact Name of Registrant as Specifi
November 14, 2022	EX-10.6	Amendment #1 to Exchange Agreement between the Company and Auctus Fund, LLC EXHIBIT 10.6 AMENDMENT #1 TO EXCHANGE AGREEMENT THIS AMENDMENT #1 to the Exchange Agreement (as defined below) (the ?Amendment?) is entered into as of October 18, 2022, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and Auctus Fund, LLC, a Delaware limited liability company (the ?Holder?) (collectively the ?Parties?). BACKGROUND A. The Company and Holder are the
October 24, 2022	SC 13G	GTHP / Guided Therapeutics, Inc. / Auctus Fund Management Llc Passive Investment SC 13G 1 gthpv3.hm.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Guided Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 40171F501 (CUSIP Number) October 11, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriat
September 15, 2022	EX-10.4	Form of Warrants issued to Auctus Fund, LLC (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed on September 15, 2022) EXHIBIT 10.4 EXHIBIT D NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECT
September 15, 2022	EX-4.1	Form of Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on 8-K, filed on September 15, 2022 EXHIBIT 4.1 EXHIBIT C NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTI
September 15, 2022	EX-99.1	5835 Peachtree Corners East, Suite B Peachtree Corners, GA 30092 EXHIBIT 99.1 5835 Peachtree Corners East, Suite B Peachtree Corners, GA 30092 Guided Therapeutics Closes $3.3 Million Dollar Bridge Financing Peachtree Corners, GA (September 7, 2022) - Guided Therapeutics, Inc. or the ?Company? (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it had raised approximately $3.3 milli
September 15, 2022	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2022 GUIDED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-22179 58-2029543 (State or other jurisdiction of incorporation) (Commissi
September 15, 2022	EX-10.3	Form of Warrants issued to Auctus Fund, LLC (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed on September 15, 2022) EXHIBIT 10.3 EXHIBIT C NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECT
September 15, 2022	EX-10.2	Exchange Agreement, dated as of September 1, 2022, by and between Guided Therapeutics, Inc. and Auctus Fund, LLC (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on September 15, 2022) EXHIBIT 10.2 EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (this ?Agreement?) is made and entered into effective as of September 1, 2022, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the ?Company?) and Auctus Fund, LLC, a Delaware limited liability company (the ?Creditor?). W I T N E S S E T H : WHEREAS, the Creditor is the payee of certain obligations owed to the Creditor by the
September 15, 2022	EX-10.1	Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on September 15, 2022) EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of September 1, 2022 between Guided Therapeutics, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and condi
September 15, 2022	EX-4.2	Form of Warrant (incorporated by reference to Exhibit 4.2 to the Current Report on 8-K, filed on September 15, 2022 EXHIBIT 4.2 EXHIBIT D NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTI
August 15, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934 For the quarterly period ended June 30, 2022 Commission File No. 0-22179 GUIDED THERAPEUTICS, INC. (Exact Name of Registrant as Specified in
July 29, 2022	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2022 GUIDED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-22179 58-2029543 (State or other jurisdiction of incorporation) (Commission F
July 29, 2022	EX-3.1	Certificate of Correction of the Certificate of Amendment of the Amended and Restated Certificate of Incorporation, filed with the Secretary of State of the State of Delaware on July 25, 2022 EXHIBIT 3.1 STATE OF DELAWARE CERTIFICATE OF CORRECTION Guided Therapeutics, Inc., a corporation organized and existing under and by virtue of the laws of the General Corporation Law of the State of Delaware, does hereby certify that: 1. The name of the corporation is Guided Therapeutics, Inc. 2. A certificate of amendment to the certificate of incorporation (the ?Certificate of Amendment?) was fi
July 13, 2022	S-1/A	As filed with the Securities and Exchange Commission on July 12, 2022 As filed with the Securities and Exchange Commission on July 12, 2022 Registration No.
July 13, 2022	EX-FILING FEES.107	Filing Fees EX-FILING FEES.107 4 gthpex107.htm FILLING FEE TABLE EXHIBIT 107 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Proposed Maximum Aggregate Offering Price(1)(2) Amount of Registration Fee(3)(4) Common stock, par value $ 10,465,000 $ 970.11 Common stock Purchase Warrants - - Shares of common stock underlying shares of common stock purchase warrants $ 10,465,000 $
July 13, 2022	EX-4.35	Form of Public Warrant EXHIBIT 4.35 COMMON STOCK PURCHASE WARRANT GUIDED THERAPEUTICS, INC. Warrant Shares: Initial Exercise Date: , 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the ?Initial E
July 6, 2022	EX-99.A	JOINT FILING AGREEMENT Exhibit A JOINT FILING AGREEMENT The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of Guided Therapeutics, Inc.
July 6, 2022	SC 13G	GTHP / Guided Therapeutics, Inc. / Rosalind Advisors, Inc. - SC 13G Passive Investment SC 13G 1 guided13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Guided Therapeutics, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 40171F501 (CUSIP Number) June 22, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to
June 30, 2022	EX-FILING FEES.107	Filing Fees EX-FILING FEES.107 7 gthpex107.htm FILLING FEE TABLE EXHIBIT 107 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Proposed Maximum Aggregate Offering Price(1)(2) Amount of Registration Fee(3)(4) Common stock, par value $ 10,235,000 $ 948.79 Common stock Purchase Warrants Shares of common stock underlying shares of common stock purchase warrants $ 10,235,000 $ 948.
June 30, 2022	EX-10.61	Exchange Agreement, dated as of June 23, 2020, by and between Guided Therapeutics, Inc. and James Clavijo (incorporated by reference to Exhibit 10.61 to the registration statement on Form S-1/A (No. 333-259871) filed on June 30, 2022) EXHIBIT 10.61 EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (this ? Agreement?) is made and entered into effective as of the 23 day of June, 2020, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the ?Company?) and the undersigned creditor of the Company (the ?Creditor?). W I T N E S S E T H : WHEREAS, the Creditor is the payee of certain obligations owed to the Creditor by the Compa
June 30, 2022	EX-1.1	Form of Underwriting Agreement EXHIBIT 1.1 SHARES OF COMMON STOCK, PRE-FUNDED WARRANTS (EXERCISABLE FOR SHARES) AND COMMON WARRANTS (EXERCISABLE FOR SHARES) OF GUIDED THERAPEUTICS, INC. UNDERWRITING AGREEMENT , 2022 Roth Capital Partners, LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Ge
June 30, 2022	EX-4.36	Form of Warrant Agency Agreement EXHIBIT 4.36 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2022 (?Agreement?), among Guided Therapeutics, Inc., a Delaware corporation (the ?Company?), and Computershare, Inc., a Delaware corporation (?Computershare?), and its wholly-owned subsidiary, Computershare Trust Company, N.A., a federally chartered trust company (collectively with Computershare, the ?Warrant Agent?). W
June 30, 2022	S-1/A	As filed with the Securities and Exchange Commission on June 29, 2022 As filed with the Securities and Exchange Commission on June 29, 2022 Registration No.
May 16, 2022	10-Q	UNITED STATES SECURITIES ANDEXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE UNITED STATES SECURITIES ANDEXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934 For the quarterly period ended March 31, 2022 Commission File No. 0-22179 GUIDED THERAPEUTICS, INC. (Exact Name of Registrant as Specified in
March 30, 2022	EX-4.47	Form of Common Stock Purchase Warrant (Iron Stone Capital) dated August 10, 2021 (incorporated by reference to Exhibit 4.47 to the annual report on Form 10-K filed March 30, 2022) EXHIBIT 4.47 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
March 30, 2022	EX-10.88	Exchange Agreement dated February 1, 2022, by and between Guided Therapeutics, Inc. and Auctus Fund LLC (incorporated by reference to Exhibit 10.87 to the annual report on Form 10-K filed March 30, 2022) EXHIBIT 10.88 GUIDED THEREAPEUTICS, INC. February 10, 2022 Auctus Fund, LLC Re: Extension of Termination Date Dear Holder: Reference is made to that certain Exchange Agreement, dated as of June 2, 2021 (the ?Agreement?) made by Guided Therapeutics, Inc. (the ?Company??) and Auctus Fund, LLC (?Auctus?). Section 3(c) of the Agreement provides, in part, that the obligations under the Agreement shall
March 30, 2022	EX-4.46	Form of Common Stock Purchase Warrant (Aspen Capital) dated May 31, 2021 (incorporated by reference to Exhibit 4.46 to the annual report on Form 10-K filed March 30, 2022) EXHIBIT 4.46 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
March 30, 2022	EX-10.79	Exchange Agreement, dated as of December 20, 2021, by and between Guided Therapeutics, Inc. and Gene S. Cartwright (incorporated by reference to Exhibit 10.79 to the annual report on Form 10-K filed March 30, 2022) EXHIBIT 10.79 SERIES D PREFERRED STOCK FINANCING GROUP WARRANT EXCHANGE AND EXERCISE AGREEMENT Gene S. Cartwright This EXCHANGE AGREEMENT (this ?Agreement?) is made and entered into effective as of the 20th day of December, 2021, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the ?Company?) and the undersigned warrant holder of the Company (the ?Warrant Holder?). W I T N E S S E
March 30, 2022	EX-10.74	Exchange Agreement, dated as of December 10, 2021, by and between Guided Therapeutics, Inc. and John Imhoff, M.D. (incorporated by reference to Exhibit 10.74 to the annual report on Form 10-K filed March 30, 2022) EXHIBIT 10.74 DECEMBER 30 2019 EQUITY FOR DEBT EXCHANGE GROUP WARRANT EXCHANGE AND EXERCISE AGREEMENT John Imhoff, M.D. This EXCHANGE AGREEMENT (this ?Agreement?) is made and entered into effective as of the 10th day of December, 2021, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the ?Company?) and the undersigned warrant holder of the Company (the ?Warrant Holder?). W I T N E
March 30, 2022	EX-10.80	Exchange Agreement, dated as of December 20, 2021, by and between Guided Therapeutics, Inc. and Mark L. Faupel (incorporated by reference to Exhibit 10.80 to the annual report on Form 10-K filed March 30, 2022) EXHIBIT 10.80 SERIES D PREFERRED STOCK FINANCING GROUP WARRANT EXCHANGE AND EXERCISE AGREEMENT Mark L. Faupel This EXCHANGE AGREEMENT (this ?Agreement?) is made and entered into effective as of the 20th day of December, 2021, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the ?Company?) and the undersigned warrant holder of the Company (the ?Warrant Holder?). W I T N E S S E T H
March 30, 2022	EX-4.48	Form of Common Stock Purchase Warrant dated November 4, 2021 (incorporated by reference to Exhibit 4.48 to the annual report on Form 10-K filed March 30, 2022) EXHIBIT 4.48 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
March 30, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934 Commission File No. 0-22179 GUIDED THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its
March 30, 2022	EX-10.76	Exchange Agreement, dated as of December 13, 2021, by and between Guided Therapeutics, Inc. and Frederick Grimm (incorporated by reference to Exhibit 10.76 to the annual report on Form 10-K filed March 30, 2022) EXHIBIT 10.76 DECEMBER 30 2019 EQUITY FOR DEBT EXCHANGE GROUP WARRANT EXCHANGE AND EXERCISE AGREEMENT Frederick Grimm This EXCHANGE AGREEMENT (this ?Agreement?) is made and entered into effective as of the 13th day of December, 2021, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the ?Company?) and the undersigned warrant holder of the Company (the ?Warrant Holder?). W I T N E S
March 30, 2022	EX-10.82	Exchange Agreement, dated as of December 21, 2021, by and between Guided Therapeutics, Inc. and GPB Debt Holdings II LLC (incorporated by reference to Exhibit 10.82 to the annual report on Form 10-K filed March 30, 2022) EXHIBIT 10.82 WARRANT EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (this ?Agreement?) is made and entered into effective as of the 21st day of December, 2021 by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the ?Company?) and the undersigned investor of the Company (the ?Investor?). W I T N E S S E T H : WHEREAS, the Investor is the holder of a warrant agreement for 7,185,000 shares
March 30, 2022	EX-10.77	Exchange Agreement, dated as of December 16, 2021, by and between Guided Therapeutics, Inc. and Richard P. Blumberg, Esq. (incorporated by reference to Exhibit 10.77 to the annual report on Form 10-K filed March 30, 2022) EXHIBIT 10.77 DECEMBER 30 2019 EQUITY FOR DEBT EXCHANGE GROUP WARRANT EXCHANGE AND EXERCISE AGREEMENT Richard P. Blumberg, Esq. This EXCHANGE AGREEMENT (this ?Agreement?) is made and entered into effective as of the 16th day of December, 2021, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the ?Company?) and the undersigned warrant holder of the Company (the ?Warrant Holder?). W
March 30, 2022	EX-10.75	Exchange Agreement, dated as of December 20, 2021, by and between Guided Therapeutics, Inc. and John Gould (incorporated by reference to Exhibit 10.75 to the annual report on Form 10-K filed March 30, 2022) EXHIBIT 10.75 DECEMBER 30 2019 EQUITY FOR DEBT EXCHANGE GROUP WARRANT EXCHANGE AND EXERCISE AGREEMENT John Gould This EXCHANGE AGREEMENT (this ?Agreement?) is made and entered into effective as of the 20th day of December, 2021, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the ?Company?) and the undersigned warrant holder of the Company (the ?Warrant Holder?). W I T N E S S E
March 30, 2022	EX-10.78	Exchange Agreement, dated as of December 16, 2021, by and between Guided Therapeutics, Inc. and K2 Medical, LLC (incorporated by reference to Exhibit 10.78 to the annual report on Form 10-K filed March 30, 2022) EXHIBIT 10.78 DECEMBER 30 2019 EQUITY FOR DEBT EXCHANGE GROUP WARRANT EXCHANGE AND EXERCISE AGREEMENT K2 Medical, LLC This EXCHANGE AGREEMENT (this ?Agreement?) is made and entered into effective as of the 16th day of December, 2021, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the ?Company?) and the undersigned warrant holder of the Company (the ?Warrant Holder?). W I T N E S
March 30, 2022	EX-10.83	Exchange Agreement, dated as of December 21, 2021, by and between Guided Therapeutics, Inc. and Michael C. James (incorporated by reference to Exhibit 10.83 to the annual report on Form 10-K filed March 30, 2022) EXHIBIT 10.83 DECEMBER 30 2019 EQUITY FOR DEBT EXCHANGE GROUP WARRANT EXCHANGE AND EXERCISE AGREEMENT Michael C. James This EXCHANGE AGREEMENT (this ?Agreement?) is made and entered into effective as of the 21st day of December, 2021, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the ?Company?) and the undersigned warrant holder of the Company (the ?Warrant Holder?). W I T N E
March 30, 2022	EX-10.86	Promissory Note, dated December 31, 2021, by and between Guided Therapeutics, Inc. and William Wells (incorporated by reference to Exhibit 10.86 to the annual report on Form 10-K filed March 30, 2022) EXHIBIOT 10.86 PROMISSORY NOTE Per Exchange Agreement dated July 9, 2020. Original Issuance Date: December 31, 2021 Principal Amount: $97,052.32 THIS PROMISSORY NOTE is duly authorized and validly Note of Guided Therapeutics, Inc., a Delaware corporation, (the ?Company?), having its principal place of business at 5835 Peachtree Corners East, Suite B, Norcross, Georgia 30092. FOR VALUE RECEIVED, th
March 30, 2022	EX-3.8	Certificate of Designation of Preferences, Rights and Limitations of Series G Convertible Preferred Stock (incorporated by reference to Exhibit 3.8 to the annual report on Form 10-K filed March 30, 2022) EXHIBIT 3.8 CERTIFICATE OF DESIGNATION, PREFERENCE AND RIGHTS OF SERIES G OF GUIDED THERAPEUTICS, INC. The undersigned, Gene Cartwright, hereby certifies that: 1. I am the President and Chief Executive Officer of GUIDED THERAPEUTICS, INC., a Delaware corporation (the ?Company?). 2. The Company is authorized to issue 5,000,000 shares of preferred stock, par value $0.001 per share (the ?Preferred St
March 30, 2022	EX-10.85	Exchange Agreement, dated as of December 30, 2021, by and between Guided Therapeutics, Inc. and Dolores Maloof (incorporated by reference to Exhibit 10.85 to the annual report on Form 10-K filed March 30, 2022) EXHIBIT 10.85 SERIES D PREFERRED STOCK FINANCING GROUP WARRANT EXCHANGE AND EXERCISE AGREEMENT Dolores Maloof This EXCHANGE AGREEMENT (this ?Agreement?) is made and entered into effective as of the 30th day of December, 2021, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the ?Company?) and the undersigned warrant holder of the Company (the ?Warrant Holder?). W I T N E S S E T H
March 30, 2022	EX-10.73	Agreement dated September 30, 2021, by and between Guided Therapeutics, Inc. and Richard P. Blumberg (incorporated by reference to Exhibit 10.73 to the annual report on Form 10-K filed March 30, 2022) EXHIBIT 10.73 AGREEMENT THIS AGREEMENT is dated September 30, 2021 (the ?Effective Date?) BETWEEN: Guided Therapeutics, Inc. (?GTI? or ?the Company?), a US registered public company incorporated in the State of Delaware with a registered and records office at 5835 Peachtree Corners East, Suite B Peachtree Corners, GA 30092. AND: Richard P. Blumberg an individual with an address at 2356 Hobart Ave
March 30, 2022	EX-10.81	Exchange Agreement, dated as of December 21, 2021, by and between Guided Therapeutics, Inc. and Flynn D. Case Living Trust (incorporated by reference to Exhibit 10.81 to the annual report on Form 10-K filed March 30, 2022) EXHIBIT 10.81 DECEMBER 30 2019 EQUITY FOR DEBT EXCHANGE GROUP WARRANT EXCHANGE AND EXERCISE AGREEMENT Flynn D. Case Living Trust This EXCHANGE AGREEMENT (this ?Agreement?) is made and entered into effective as of the 21st day of December, 2021, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the ?Company?) and the undersigned warrant holder of the Company (the ?Warrant Holder?).
March 30, 2022	EX-10.84	Exchange Agreement, dated as of December 30, 2021, by and between Guided Therapeutics, Inc. and Bryan Mamula (incorporated by reference to Exhibit 10.84 to the annual report on Form 10-K filed March 30, 2022) EXHIBIT 10.84 DECEMBER 30 2019 EQUITY FOR DEBT EXCHANGE GROUP WARRANT EXCHANGE AND EXERCISE AGREEMENT Bryan Mamula This EXCHANGE AGREEMENT (this ?Agreement?) is made and entered into effective as of the 30th day of December, 2021, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the ?Company?) and the undersigned warrant holder of the Company (the ?Warrant Holder?). W I T N E S S
March 30, 2022	EX-10.87	EXCHANGE AGREEMENT EXHIBIT 10.87 EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (this ?Agreement?) is made and entered into effective as of February 1, 2022, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the ?Company?) and Auctus Fund, LLC, a Delaware limited liability company (the ?Creditor?). W I T N E S S E T H : WHEREAS, the Creditor is the payee of certain obligations owed to the Creditor by the
February 17, 2022	EX-10.61	Exchange Agreement, dated as of June 23, 2020, by and between Guided Therapeutics, Inc. and James Clavijo (incorporated by reference to exhibit 10.61 to the registration statement on Form S-1/A (No. 333-259871) filed February 17, 2022) EX-10.61 6 gthpex1061.htm EXCHANGE AGREEMENT EXHIBIT 10.61 EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (this “Agreement”) is made and entered into effective as of the 23 day of June, 2020, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the “Company”) and the undersigned creditor of the Company (the “Creditor”). W I T N E S S E T H : WHEREAS, the Creditor is the payee of certain o
February 17, 2022	S-1/A	As filed with the Securities and Exchange Commission on February 17, 2022 As filed with the Securities and Exchange Commission on February 17, 2022 Registration No.
February 17, 2022	EX-FILING FEES	Filing Fees EXHIBIT 107 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Proposed Maximum Aggregate Offering Price(1)(2) Amount of Registration Fee(3)(4) Common stock, par value $ 12,000,000 $ 1,112.
February 17, 2022	EX-1.1	Form of Underwriting Agreement (incorporated by reference to Exhibit 1.1 to the annual report on Form 10-K filed March 30, 2022) EXHIBIT 1.1 SHARES OF COMMON STOCK, PRE-FUNDED WARRANTS (EXERCISABLE FOR SHARES) AND COMMON WARRANTS (EXERCISABLE FOR SHARES) OF GUIDED THERAPEUTICS, INC. UNDERWRITING AGREEMENT , 2022 Roth Capital Partners, LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Ge
February 17, 2022	EX-4.34	Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.34 to the registration statement on Form S-1/A (No. 333-259871) filed on February 17, 2022) EXHIBIT 4.34 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
February 17, 2022	EX-4.35	Form of Public Warrant EXHIBIT 4.35 COMMON STOCK PURCHASE WARRANT GUIDED THERAPEUTICS, INC. Warrant Shares: Initial Exercise Date: , 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the ?Initial E
January 7, 2022	EX-3.1	Certificate of Amendment to the Certificate of Incorporation of Guided Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed on January 7, 2022) EXHIBIT 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF GUIDED THERAPEUTICS, INC. The undersigned, for the purposes of amending the Amended and Restated Certificate of Incorporation, (the ?Amended and Restated Certificate of Incorporation?) of Guided Therapeutics, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law o
January 7, 2022	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2021 (January 6, 2022) GUIDED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-22179 58-2029543 (State or other jurisdiction of inco
November 15, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934 For the quarterly period ended September 30, 2021 Commission File No. 0-22179 GUIDED THERAPEUTICS, INC. (Exact Name of Registrant as Specifi
October 7, 2021	S-1/A	As filed with the Securities and Exchange Commission on [•], 2021 As filed with the Securities and Exchange Commission on [•], 2021 Registration No.
September 29, 2021	S-1	As filed with the Securities and Exchange Commission on [•], 2021 As filed with the Securities and Exchange Commission on [?], 2021 Registration No.
September 7, 2021	EX-2.1	Agreement between Shandong Yaohua Medical Instrument Corporation and Guided Therapeutics, Inc., Confidential, Final 12 August 2021 (incorporated by reference to Exhibit 2.1 to the current report on Form 8-K filed September 7, 2021) EXHIBIT 2.1 AGREEMENT BETWEEN SHANDONG YAOHUA MEDICAL INSTRUMENT CORPORATION AND GUIDED THERAPEUTICS, INC. CONFIDENTIAL, FINAL 12 AUGUST 2021 ?? 2021?8?12? This Agreement supersedes any and all statements, representations or agreements other than existing Purchase Orders between Guided Therapeutics, Inc, a Georgia, United States of American corporation (?GTI?) located at 5835 Peachtree Corners Eas
September 7, 2021	EX-99.1	5835 Peachtree Corners East, Suite B Peachtree Corners, GA 30092 EXHIBIT 99.1 5835 Peachtree Corners East, Suite B Peachtree Corners, GA 30092 Guided Therapeutics Receives Notification of Successful Clinical Trial Regulatory Review and $133,000 Payment from China Peachtree Corners GA (August 20, 2021) - Guided Therapeutics, Inc. (OTC:QB GTHP), the maker of the LuViva Advanced Cervical Scan, based on its patented biophotonic technology, announced today it had pa
September 7, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 GUIDED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-22179 58-2029543 (State or other jurisdiction of incorporation) (Commission
August 18, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934 For the quarterly period ended June 30, 2021 Commission File No. 0-22179 GUIDED THERAPEUTICS, INC. (Exact Name of Registrant as Specified in
August 18, 2021	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934 For the quarterly period ended March 31, 2021 Commission File No. 0-22179 GUIDED THERAPEUTICS, INC. (Exact Name of Reg
August 16, 2021	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 000-22179 NT 10-Q 1 gthpnt10q63021.htm GUIDED THERAPEUTICS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 000-22179 (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR [ ] Form N-CSR For Period Ended: June 30, 2021 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [
July 27, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2021 (July 22, 2021) GUIDED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-22179 58-2029543 (State or other jurisdiction of incorporat
July 9, 2021	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020. OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-22179
July 7, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2021 GUIDED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22179 (Commission File Number)
July 6, 2021	DEF 14A	SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Solicitation Material Under Rule 14a-12 GUIDED THERAPEUTICS, INC.
June 22, 2021	PRE 14A	SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 PRE 14A 1 gthppre14a621212.htm GUIDED THERAPEUTICS, INC. SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission
June 10, 2021	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2021 GUIDED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22179 (Commission File Number)
June 10, 2021	EX-10.1	GUIDED THERAPEUTICS, INC. 5835 Peachtree Corners East, Suite B Norcross, Georgia 30092 April __, 2021 Exhibit 10.1 GUIDED THERAPEUTICS, INC. 5835 Peachtree Corners East, Suite B Norcross, Georgia 30092 April , 2021 Purchasers pursuant to Securities Purchase Agreement Dated December 23, 2020 Re: Creation of Series F-2 Convertible Preferred Stock Dear Purchaser: As previously disclosed in the public filings of Guided Therapeutics, Inc. (the ?Company?), the recent private placement pursuant to the Se
June 10, 2021	EX-3.1	Certificate of Designation of Preferences, Rights and Limitations of Series F-2 Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed on June 10, 2021) Exhibit 3.1 GUIDED THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES F-2 CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Gene S. Cartwright, does hereby certify that: 1. He is the President, Chief Executive Officer, and acting Chief Financial Officer of Guided Therapeutics, Inc., a Delaware co
May 21, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCH UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934 For the quarterly period ended March 31, 2021 Commission File No. 0-22179 GUIDED THERAPEUTICS, INC. (Exact Name of Registrant as Specifi
May 17, 2021	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 000-22179 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 000-22179 (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR [ ] Form N-CSR For Period Ended: March 31, 2021 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form N-SAR For the Transition Period Ended: Nothing in the form shall be construed to imply that Commission has verified any information contained herein.
April 7, 2021	EX-10.59	Finder’s Fee Agreement with JH Darbie, dated as of May 19, 2020 (incorporated by reference to Exhibit 10.59 to the annual report on Form 10-K filed April 5, 2021) Exhibit 10.59 Guided Therapeutics, Inc. 5835 Peachtree Comers East, Suite B Norcross, GA 30092 Re: Finder's Fee Agreement Dear Gene Cartwright: As you know, Guided Therapeutics, Inc. (the ' Issuer"), has expressed an interest in obtaining private equity or debt capital for various purposes. This letter agreement ("Agreement") sets forth the terms and conditions upon which J.H. Darbi.e & Co., Inc.
April 7, 2021	EX-3.5	Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible Preferred Stock (incorporated by reference to Exhibit 3.5 to the annual report on Form 10-K filed April 5, 2021) Exhibit 3.5 EXHIBIT A. GUIDED THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES E CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Gene S. Cartwright, does hereby certify that: 1. He is the President, Chief Executive Officer, and acting Chief Financial Officer of Guided Therapeutics, Inc., a De
April 7, 2021	EX-4.42	Form of Warrant (Manju Venugopal), dated August 10, 2020 (incorporated by reference to Exhibit 4.42 to the annual report on Form 10-K filed April 5, 2021) Exhibit 4.42 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
April 7, 2021	EX-10.65	Securities Purchase Agreement with PowerUp, dated as of February 10, 2021 (incorporated by reference to Exhibit 10.65 to the annual report on Form 10-K filed April 5, 2021) Exhibit 10.65 SERIES G PREFERRED STOCK PURCHASE AGREEMENT This SERIES G PREFERRED STOCK PURCHASE AGREEMENT (the "Agreement"), dated as of February 2, 2021, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation, with its address at 5835 Peachtree Corners East, Suite B, Norcross, Georgia 30092 (the "Company"), and POWER UP LENDING GROUP, LTD., a New York corporation, with its address at 1
April 7, 2021	EX-3.6	Certificate of Designation of Preferences, Rights and Limitations of Series F Convertible Preferred Stock (incorporated by reference to Exhibit 3.6 to the annual report on Form 10-K filed April 5, 2021) Exhibit 3.6 EXHIBIT A. GUIDED THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES F CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Gene S. Cartwright, does hereby certify that: 1. He is the President, Chief Executive Officer, and acting Chief Financial Officer of Guided Therapeutics, Inc., a De
April 7, 2021	EX-10.66	Consulting Agreement with Richard Blumberg, dated as of March 11, 2021 (incorporated by reference to Exhibit 10.66 to the annual report on Form 10-K filed April 5, 2021) Exhibit 10.66 THIS AGREEMENT is dated March.10, 2021 (the "Effective Datel') BETWEEN: Guided Therapeutics. Inc. ("GTI" or lithe Company"), a US registered public company incorporated in the State of Delaware with a registered and records office at 5835 Peachtree Corners East,?Suite B, Peachtree Corners, GA 30092. AND: Richard P. Blumberg an Individual with an address at 2356 Hobart Ave. SW, Seattl
April 7, 2021	EX-10.62	Finder’s Fee Agreement with FCMI, dated as of June 11, 2020 (incorporated by reference to Exhibit 10.62 to the annual report on Form 10-K filed April 5, 2021) Exhibit 10.62 AMENDED FINDER'S FEE AGREEMENT THIS AMENDMENT TO THE AMENDED FINDER'S FEE AGREEMENT IS DATED JUNE 11, 2020 (the Effective Date") BETWEEN: Guided Therapeutics Inc., a US registered public company incorporated in the State of Delaware with a registered and records office at 5835 Peachtree Corners East, Suite B Norcross GA 30092. ("the Company") AND Fieldhouse Capital Management Inc., a
April 7, 2021	EX-4.44	Note Payable Agreement with Mark Faupel, dated February 19, 2021 (incorporated by reference to Exhibit 4.44 to the annual report on Form 10-K filed April 5, 2021) Exhibit 4.44 PROMISSORY NOTE Per Board Compensation Committee Memo dated February 19, 2021. (Replaces long term note payable of original principal of $207,110.86, dated September 4, 2018) Original Issuance Date: February 19, 2021 Principal Amount: $153,177.69 THIS PROMISSORY NOTE is duly authorized and validly Note of Guided Therapeutics, Inc., a Delaware corporation, (the ?Company?), having its p
April 7, 2021	EX-10.64	Securities Purchase Agreement with PowerUp, dated as of December 24, 2020 (incorporated by reference to Exhibit 10.64 to the annual report on Form 10-K filed April 5, 2021) Exhibit 10.64 SERIES G PREFERRED STOCK PURCHASE AGREEMENT This SERIES G PREFERRED STOCK PURCHASE AGREEMENT (the "Agreement"), dated as of December 23, 2020, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation, with its address at 5835 Peachtree Corners East, Suite B, Norcross, Georgia 30092 (the "Company"), and POWER UP LENDING GROUP LTD., a New York corporation, with its address at 1
April 7, 2021	EX-4.37	Form of Warrant (Series D Preferred Stock) (incorporated by reference to Exhibit 4.37 to the annual report on Form 10-K filed April 5, 2021) Exhibit 4.37 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
April 7, 2021	EX-4.43	Note Payable Agreement with Gene Cartwright, dated February 19, 2021 (incorporated by reference to Exhibit 4.43 to the annual report on Form 10-K filed April 5, 2021) Exhibit 4.43 PROMISSORY NOTE Per Board Compensation Committee Memo dated February 19, 2021. (Replaces long term note payable of original principal of $319,204.30, dated September 4, 2018) Original Issuance Date: February 19, 2021 Principal Amount: $267,085.25 THIS PROMISSORY NOTE is duly authorized and validly Note of Guided Therapeutics, Inc., a Delaware corporation, (the ?Company?), having its p
April 7, 2021	EX-4.45	Form of Warrant (Aspen Capital), dated June 23, 2020 (incorporated by reference to Exhibit 4.45 to the annual report on Form 10-K filed April 5, 2021) Exhibit 4.45 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
April 7, 2021	EX-4.41	Form of Warrant (James Clavijo), dated June 23, 2020 (incorporated by reference to Exhibit 4.41 to the annual report on Form 10-K filed April 5, 2021) Exhibit 4.41 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
April 7, 2021	EX-4.36	Form of Warrant (Series D Preferred Stock) (incorporated by reference to Exhibit 4.36 to the annual report on Form 10-K filed April 5, 2021) Exhibit 4.36 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
April 7, 2021	EX-10.67	Exchange Agreement with Richard Fowler, dated as of March 22, 2021 (incorporated by reference to Exhibit 10.67 to the annual report on Form 10-K filed April 5, 2021) Exhibit 10.67 EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (this "Agreement") is made and entered into effective as of the day of March, 2021 by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the "Company") and the undersigned creditor of the Company (the "Creditor"). W I T N E S S E T H : WHEREAS, the Creditor is the payee of certain obligations owed to the Creditor by the Company a
April 7, 2021	EX-10.60	Debt for Equity Exchange Agreement with Auctus, dated as of May 22, 2020 (incorporated by reference to Exhibit 10.60 to the annual report on Form 10-K filed April 5, 2021) Exhibit 10.60 EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (this ?Agreement?) is made and entered into effective as of May 22, 2020, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the ?Company?) and Auctus Fund, LLC, a Delaware limited liability company (the ?Creditor?). W I T N E S S E T H : WHEREAS, the Creditor is the payee of certain obligations owed to the Creditor by the Com
April 7, 2021	EX-10.68	Securities Purchase Agreement for Series E Preferred Stock (incorporated by reference to Exhibit 10.68 to the annual report on Form 10-K filed April 5, 2021) Exhibit 10.68 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of July 1, 2020, between Guided Therapeutics, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and conditio
April 7, 2021	EX-4.24	Convertible Promissory Note with Auctus, dated March 31, 2020 (incorporated by reference to Exhibit 4.34 to the annual report on Form 10-K filed April 5, 2021) Exhibit 4.24 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR
April 7, 2021	EX-10.61	Securities Purchase Agreement with Auctus, dated as of May 27, 2020 (incorporated by reference to Exhibit 10.61 to the annual report on Form 10-K filed April 5, 2021) Exhibit 10.61 AMENDMENT # 1 TO THE SECURITIES PURCHASE AGREEMENT AND SENIOR SECURED CONVERTIBLE PROMISSORY NOTE DATED DECEMBER 17, 2019 THIS AMENDMENT #1 (the ?Amendment?) TO THE SECURITIES PURCHASE AGREEMENT AND SENIOR SECURED CONVERTIBLE PROMISSORY NOTE dated December 17, 2019, is made effective as of May 27, 2020 (the ?Effective Date?), by and between Guided Therapeutics, Inc. a Delaware corpor
April 7, 2021	EX-4.38	Form of Warrant (Ironstone Capital), dated April 23, 2020 (incorporated by reference to Exhibit 4.38 to the annual report on Form 10-K filed April 5, 2021) Exhibit 4.38 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
April 7, 2021	EX-4.39	Form of Warrant (Auctus Note), dated May 22, 2020 (incorporated by reference to Exhibit 4.39 to the annual report on Form 10-K filed April 5, 2021) Exhibit 4.39 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAYBE EXERCISED HA VE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE RE
April 7, 2021	EX-4.35	Form of Warrant (Auctus Note), dated March 31, 2020 (incorporated by reference to Exhibit 4.35 to the annual report on Form 10-K filed April 5, 2021) Exhibit 4.35 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAYBE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG
April 7, 2021	EX-4.40	Form of Warrant (Credential Qtrade Securities Inc. ITF Reve Royalty Income Growth, dated as of June 23, 2020) (incorporated by reference to Exhibit 4.40 to the annual report on Form 10-K filed April 5, 2021) Exhibit 4.40 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
April 7, 2021	EX-10.69	Securities Purchase Agreement (Series F), dated March 31, 2020 (incorporated by reference to Exhibit 10.68 to the annual report on Form 10-K filed April 5, 2021) Exhibit 10.69 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of December 23, 2020, between Guided Therapeutics, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and con
April 7, 2021	10-K	Annual Report - ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020. OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-22179 GUIDED THERAPEUTI
April 7, 2021	EX-10.63	Exchange Agreement with William Wells, dated as of July 9, 2020 (incorporated by reference to Exhibit 10.63 to the annual report on Form 10-K filed April 5, 2021) Exhibit 10.63 EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (this "Agreement") is made and entered into effective as of the 9th day of July, 2020 by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the "Company") and the undersigned creditor of the Company (the "Creditor"). W I T N E S S E T H : WHEREAS, the Creditor is the payee of certain obligations owed to the Creditor by the Compan
March 31, 2021	NT 10-K	- GUIDED THERAPEUTICS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 000-22179 (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form N-SAR [ ] Form N-CSR For Period Ended: December 31, 2020 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form N-SAR For the Transition Period Ended: Nothing in the form shall be construed to imply that Commission has verified any information contained herein.
November 5, 2020	10-Q/A	Quarterly Report - GUIDED THERAPEUTICS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934 For the quarterly period ended September 30, 2020 Commission File No. 0-22179 GUIDED THERAPEUTICS, INC. (Exact Name of
November 5, 2020	10-Q	Quarterly Report - GUIDED THERAPEUTICS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934 For the quarterly period ended September 30, 2020 Commission File No. 0-22179 GUIDED THERAPEUTICS, INC. (Exact Name of Registrant as Spe
October 13, 2020	CORRESP	Guided Therapeutics, Inc. 5835 Peachtree Corners East, Suite B Norcross, Georgia 30092 Guided Therapeutics, Inc. 5835 Peachtree Corners East, Suite B Norcross, Georgia 30092 October 13, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Timothy Buchmiller Re: Guided Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-248712 Dear Mr. Buchmiller: Pursuant to Rule 461 under the Sec
October 8, 2020	S-1/A	- S-1/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 To FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Guided Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 3845 58-2029543 (State or jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (IRS Employer Identifica
October 8, 2020	EX-3.5	GUIDED THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS SERIES E CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW Exhibit 3.5 GUIDED THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES E CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Gene S. Cartwright, does hereby certify that: 1. He is the President, Chief Executive Officer, and acting Chief Financial Officer of Guided Therapeutics, Inc., a Delaware corp
September 16, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - GUIDED THERAPEUTICS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2020 GUIDED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-22179 (Commission File
September 10, 2020	S-1	Registration Statement - FORM S-1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Guided Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 3845 58-2029543 (State or jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (IRS Employer Identification No.) 5835 Peac
August 20, 2020	10-Q	Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934 For the quarterly period ended June 30, 2020 Commission File No. 0-22179 GUIDED THERAPEUTICS, INC. (Exact Name of Registrant as Specifie
August 17, 2020	NT 10-Q	- GUIDED THERAPEUTICS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 000-22179 (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR [ ] Form N-CSR For Period Ended: June 30, 2020 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form N-SAR For the Transition Period Ended: Nothing in the form shall be construed to imply that Commission has verified any information contained herein.
July 7, 2020	10-Q	Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934 For the quarterly period ended March 31, 2020 Commission File No. 0-22179 GUIDED THERAPEUTICS, INC. (Exact Name of Registrant as Specified i
June 29, 2020	NT 10-Q	- GUIDED THERAPEUTICS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 000-22179 (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR [ ] Form N-CSR For Period Ended: March 31, 2020 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form N-SAR For the Transition Period Ended: Nothing in the form shall be construed to imply that Commission has verified any information contained herein.
May 18, 2020	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2020 GUIDED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22179 (Commission File Number)
April 20, 2020	EX-10.43	EXCHANGE AGREEMENT Exhibit 10.43 EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (this "Agreement") is made and entered into effective as of the day of December, 2019, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the "Company") and the undersigned creditor of the Company (the "Creditor"). WITNESSETH: WHEREAS, the Creditor is the payee of certain obligations owed to the Creditor by the Company as set
April 20, 2020	EX-10.20	SECURITIES PURCHASE AGREEMENT Exhibit 10.20 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of April 30, 2018, by and between Guided Therapeutics, Inc., a Delaware corporation, with its address at 5835 Peachtree Corners East, Suite D, Norcross, Georgia 30092 (the “Company”), and POWER UP LENDING GROUP LTD., a Virginia corporation, with its address at 111 Great Neck Road, Suite 216,
April 20, 2020	EX-10.21	SECURITIES PURCHASE AGREEMENT Exhibit 10.21 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of June 7, 2018, by and between Guided Therapeutics, Inc., a Delaware corporation, with its address at 5835 Peachtree Corners East, Suite D, Norcross, Georgia 30092 (the "Company"), and POWER UP LENDING GROUP LTD., a Virginia corporation, with its address at 111 Great Neck Road, Suite 216, Gr
April 20, 2020	EX-10.28	PROMISSORY NOTE (Replaces deferred compensation of $319,204.30) Exhibit 10.28 PROMISSORY NOTE (Replaces deferred compensation of $319,204.30) $319,204.30 September 4, 2018 FOR VALUE RECEIVED, Guided Therapeutics, Inc., a Delaware corporation (referred to hereinafter as “Maker” and “Company”), hereby promises to pay to Gene Cartwright (“Holder”) the principal sum of Three Hundred Nineteen Thousand, Two Hundred Four Dollars and Thirty Cents ($319,204.30), plus a
April 20, 2020	EX-4.31	12% SENIOR SECURED DEBENTURE DUE __________ ___, 20221 Exhibit 4.31 THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVA
April 20, 2020	EX-4.27	SENIOR SECURED CONVERTIBLE PROMISSORY NOTE Exhibit 4.27 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR
April 20, 2020	EX-10.48	FORM OF ADDITIONAL DEBTOR JOINDER Security Agreement dated as of December 30, 2019 made by Guided Therapeutics, Inc. and its subsidiaries party thereto from time to time, as Debtors to and in favor of the Secured Parties identified therein (the “Secu Exhibit 10.48 FORM OF ADDITIONAL DEBTOR JOINDER Security Agreement dated as of December 30, 2019 made by Guided Therapeutics, Inc. and its subsidiaries party thereto from time to time, as Debtors to and in favor of the Secured Parties identified therein (the “Security Agreement”) Reference is made to the Security Agreement as defined above; capitalized terms used herein and not otherwise defined h
April 20, 2020	EX-10.18	SECURITIES PURCHASE AGREEMENT Exhibit 10.18 SECURITIES PURCHASE AGREEMENT THIS PURCHASE AGREEMENT ("Agreement") is made as of the 17th day of May, 2018 by and between Guided Therapeutics, Inc., (the "Company"), and GHS Investments, LLC (the "Investor"). Recitals A. The Investor wishes to purchase from the Company and the Company wishes to sell and issue to the Investor, upon the terms and conditions stated in this Agreement: 1
April 20, 2020	EX-10.16	FIRST AMENDMENT TO LEASE Exhibit 10.16 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (the "Amendment") is made this 23 day of February, 2018 (the "Effective Date"), between COLFIN COBALT I-II OWNER, LLC, a Delaware limited liability company ("Landlord"), and GUIDED THERAPEUTICS, INC., a Delaware corporation ("Tenant"). W I T N E S E T H: WHEREAS, Landlord, as successor-in-interest to Cobalt Industrial REIT, and T
April 20, 2020	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019. OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-22179 GUIDED THERAPEUTICS,
April 20, 2020	EX-10.29	EQUITY FINANCING AGREEMENT Exhibit 10.29 EQUITY FINANCING AGREEMENT This EQUITY FINANCING AGREEMENT (the “Agreement”), dated as of March 1, 2018 (the “Execution Date”), is entered into by and between Guided Therapeutics, Inc., a Delaware corporation with its principal executive office at 5835 Peachtree Corners East, Norcross, Georgia 30092 (the “Company”),and GHS Investments LLC, a Nevada limited liability company, with off
April 20, 2020	EX-10.30	BUSINESS FUNDING PAYMENT RIGHTS PURCHASE AND SALE AGREEMENT This Payment Rights Purchase and Sale Agreement ("Agreement") dated 02/14/2019. is made by and between EBF Partners, LLC d/b/a Everest Business Funding ("Purchaser") and the business identif Exhibit 10.30 BUSINESS FUNDING PAYMENT RIGHTS PURCHASE AND SALE AGREEMENT This Payment Rights Purchase and Sale Agreement ("Agreement") dated 02/14/2019. is made by and between EBF Partners, LLC d/b/a Everest Business Funding ("Purchaser") and the business identified below ("Seller"). SELLER'S IN FORMATION OFFER TO SELL AND PURCHASE PAYMENT RIGHTS Seller hereby sells, assigns and transfers to Purc
April 20, 2020	EX-10.53	EXCHANGE AGREEMENT Exhibit 10.53 EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (this "Agreement") is made and entered into effective as of the 6th day of January, 2020, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the "Company") and the undersigned creditor of the Company (the "Creditor"). WHEREAS, the Company has entered into certain agreements with investors for a recapitalization of the Company
April 20, 2020	EX-10.54	FINDER'S FEE AGREEMENT FOR IRON STONE CAPITAL This AGREEMENT (the"Agreement") dated this ___ day of August, 2019 BETWEEN: Guided Therapeutics Inc., 5835 Peachtree Comers East, Suite D, Norcross, GA 30092 (the "Company") Iron Stone Capital 20 Scrivene Exhibit 10.54 FINDER'S FEE AGREEMENT FOR IRON STONE CAPITAL This AGREEMENT (the"Agreement") dated this day of August, 2019 BETWEEN: Guided Therapeutics Inc., 5835 Peachtree Comers East, Suite D, Norcross, GA 30092 (the "Company") -AND- Iron Stone Capital 20 Scrivener Square Suite 607 Toronto, M4W 3X9 Canada ("ISC") WHEREAS ISC has offered to provide certain services to GTI in GTI's capital raising
April 20, 2020	EX-10.52	EXCHANGE AGREEMENT Exhibit 10.52 EXCHANGE AGREEMENT THE EXCHANGE AGREEMENT (this "Agreement") is made and entered into effective as of the 30th day of December, 2019, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the "Company") and the undersigned creditor of the Company (the "Creditor"). WHEREAS, the Creditor is the payee of certain obligations owed to the Creditor by the Company as set forth on
April 20, 2020	EX-10.49	EXCHANGE AGREEMENT Exhibit 10.49 EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (this “Agreement”) is made and entered into effective as of the day of December, 2019, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the “Company”) and the undersigned creditor of the Company (the “Creditor”). W I T N E S S E T H : WHEREAS, the Creditor is the payee of certain obligations owed to the Creditor by the Compa
April 20, 2020	EX-10.39	NOTE EXCHANGE AGREEMENT Exhibit 10.39 NOTE EXCHANGE AGREEMENT Original Issuance Date: February 8, 2019 Principal Amount: $ 145,543.99 THIS PROMISSORY NOTE is duly authorized and validly Note of Guided Therapeutics, Inc., a Delaware corporation, (the "Company"), having its principal place of business at 5835 Peachtree Corners East, Suite B, Norcross, Georgia 30092. THIS PROMISSORY NOTE is issued in exchange for three note
April 20, 2020	EX-10.36	AGREEMENT BETWEEN SHANDONG YAOBUA MEDICAL INSTRUMENT CORPORATION AND GUIDED THERAPEUTICS, INC. 24 JULY 2019 Exhibit 10.36 AGREEMENT BETWEEN SHANDONG YAOBUA MEDICAL INSTRUMENT CORPORATION AND GUIDED THERAPEUTICS, INC. CONFIDENTIAL, FINAL 24 JULY 2019 This Agreement supersedes. any and all statements, representations or agreements other than existing Purchase Orders between Guided Therapeutics, Inc, a Georgia, United States of American corporation ("GTI') located at 5835 Peachtree Comers East, Suite D, No
April 20, 2020	EX-10.35	UNSECURED PROMISSORY NOTE (the "Note") Exhibit 10.35 UNSECURED PROMISSORY NOTE (the "Note") FROM: Guided Therapeutics, Inc. (the "Issuer") TO: REV ROYALTY INCOME AND GROWTH TRUST (the "Holder") AMOUNT: 65,500 CAD $ (the " Principal') LOAN ORIGINATION FEE: 8% of Above Total DATE: 1 July, 2019 1. Indebtedness. For value received, the Issuer promises to pay to, or to the order of, the Holder an amount equal to the Principal in lawfu l mon
April 20, 2020	EX-10.14	SECURITIES PURCHASE AGREEMENT Exhibit 10.14 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of February 12, 2018, by and between Guided Therapeutics, Inc., a Delaware corporation, with headquarters located at 5835 Peachtree Comers East, Suite D, Norcross, GA 30092, (the "Company"), and ADAR BAYS, LLC, a Florida limited liability company, with its address at 3411 Indian Creek Drive,
April 20, 2020	EX-10.58	SECURITIES PURCHASE AGREEMENT Exhibit 10.58 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of March 31, 2020, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation, with headquarters located at 5835 Peachtree Comers East, Suite D, Norcross, Georgia 30092 (the "Company"), and AUCTUS FUND, LLC, a Delaware limited liability company, with its address at 545 Boylston Street,
April 20, 2020	EX-4.29	COMMON STOCK PURCHASE WARRANT GUIDED THERAPEUTICS, INC. Exhibit 4.29 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
April 20, 2020	EX-4.32	COMMON STOCK PURCHASE WARRANT GUIDED THERAPEUTICS, INC. Exhibit 4.32 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
April 20, 2020	EX-10.41	SECURlTY AGREEMENT Exhibit 10.41 SECURlTY AGREEMENT THIS SECURlTY AGREEMENT (this "Agreement"), is entered into as of December 17, 2019, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the "Borrower"), and Auctus Fund, LLC, a Delaware limited liability company (the "Secured ~" or "Secured Parties"). All capitalized terms not otherwise defined herein shall the meanings ascribed to them in that certa
April 20, 2020	EX-10.37	ADDENDUM TO EXCHANGE AGREEMENT Exhibit 10.37 ADDENDUM TO EXCHANGE AGREEMENT An Agreement was made by and between GUIDED THERAPEUTICS, INC. (the "Company") and the undersigned creditor of the Company (the "Creditor") on the 241h day of July, 2018 (hereinafter referred to as "original stated contract") set forth below. WHEREAS, the parties wish to modify the terms of the original stated contract as set forth herein. NOW THEREFORE
April 20, 2020	EX-10	SECURITIES PURCHASE AGREEMENT Exhibit 10.46 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 30, 2019, between Guided Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and con
April 20, 2020	EX-10.17	SECURITIES PURCHASE AGREEMENT Exhibit 10.17 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of March 12, 2018, by and between Guided Therapeutics, Inc., a Delaware corporation, with headquarters located at 5835 Peachtree Comers East, Suite D, Norcross, GA 30092, (the "Company"), and EAGLE EQUITIES, LLC, a Nevada limited liability company, with its address at 91 Shelton Ave, Suite107
April 20, 2020	EX-10.19	SECURITIES PURCHASE AGREEMENT Exhibit 10.19 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 20, 2018, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation, with headquarters located at 5835 Peachtree Corners East, Suite D, Norcross, GA 30092 (the “Company”), and AUCTUS FUND, LLC, a Delaware limited liability company, with its address at 177 Huntington Avenue, 17
April 20, 2020	EX-10.23	SECURITIES PURCHASE AGREEMENT Exhibit 10.23 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the "Agreement'), dated as of July 3, 2018, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation, with headquarters located at 5835 Peachtree Comers East, Suite D, Norcross, GA 30092 (the "Company"), and AUCTUS FUND, LLC, a Delaware limited liability company, with its address at 545 Boylston Street, 2nd Flo
April 20, 2020	EX-10.38	ADDENDUM TO EXCHANGE AGREEMENT Exhibit 10.38 ADDENDUM TO EXCHANGE AGREEMENT An Agreement was made by and between GUIDED THERAPEUTICS, [NC. (the "Company") and the undersigned creditor of the Company (the "Creditor") on the 241h day of July, 2018 (hereinafter referred to as "original stated contract") set forth below. WHEREAS, the parties wish to modify the terms of the original stated contract as set forth herein. NOW THEREFORE
April 20, 2020	EX-10.50	EXCHANGE AGREEMENT Exhibit 10.50 EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (this "Agreement") is made and entered into effective as of the 30th day of December, 2019, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the "Company") and the undersigned creditor of the Company (the "Creditor"). WITNESSETH: WHEREAS, the Creditor is the payee of certain obligations owed to the Creditor by the Company as
April 20, 2020	EX-10.33	SECURITIES PURCHASE AGREEMENT Exhibit 10.33 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of May 15, 2019, by and between Guided Therapeutics, Inc., a Delaware corporation, with headquarters located at 5835 Peachtree Comers East, Suite B, Norcross, GA 30092, (the "Company")and EAGLE EQUITIES, LLC, a Nevada limited liability company, with its address at 390 Whalley Ave., New Haven,
April 20, 2020	EX-10.47	REGISTRATION RIGHTS AGREEMENT Exhibit 10.47 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of December 30, 2019, between Guided Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities P
April 20, 2020	EX-4.28	COMMON STOCK PURCHASE WARRANT GUIDED THERAPEUTICS, INC. Exhibit 4.28 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE RE
April 20, 2020	EX-10.57	AGREEMENT RELATED TO PROMOTIONAL ACTIVITIES Exhibit 10.57 AGREEMENT RELATED TO PROMOTIONAL ACTIVITIES THIS AGREEMENT (the Agreement") dated this day of January, 2020 BETWEEN: Guided Therapeutics Inc. of5835 Peachtree Comers East, Suite B, Norcross, GA 3009 (the "Company") -AND- Blumberg·& Bowles Consulting, LLC, 2356 Hobart Ave SW, Seattle, WA 98116 ("B&B"). WHEREAS the Company needs to enhance its relationship with current and potential in
April 20, 2020	EX-10.44	SECURITY AGREEMENT Exhibit 10.44 SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of December 30, 2019 (this “Agreement”), is among Guided Therapeutics, Inc., a Delaware corporation (the “Company”), all of the Subsidiaries of the Company (such subsidiaries, the “Guarantors” and together with the Company, the “Debtors”) and the holders (including their endorsees, transferees and assigns collectively, the “Secured
April 20, 2020	EX-10.42	REGISTRATION RIGHTS AGREEMENT Exhibit 10.42 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of December 17, 2019, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the "Company"), and AUCTUS FUND, LLC, a Delaware limited liability company (together with it permitted assigns, the "Buyer"). Capitalized terms used herein and not otherwise defined herein shall have the respe
April 20, 2020	EX-10.32	SECURITIES PURCHASE AGREEMENT Exhibit 10.32 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of March 29, 2019, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation, with headquarters located at 5835 Peachtree Comers East, Suite B, Norcross, GA 30092 (the "Company"), and AUCTUS FUND, LLC, a Delaware limited liability company, with its address at 545 Boylston Street, 2nd F
April 20, 2020	EX-10.24	PROMISSORY NOTE Exhibit 10.24 PROMISSORY NOTE Original Issuance Date: August 22, 2018 Principal Amount: $150,000.00 THIS PROMISSORY NOTE is duly authorized and validly Note of Guided Therapeutics, Inc., a Delaware corporation, (the "Company"), having its principal place of business at 5835 Peachtree Comers East, Suite D, Norcross, Georgia 30092. FOR VALUE RECEIVED, the undersigned promises to pay to the Flynn D.
April 20, 2020	EX-10.22	SECURITIES PURCHASE AGREEMENT Exhibit 10.22 SECURITIES PURCHASE AGREEMENT THIS PURCHASE AGREEMENT ("Agreement") is made as of the 22nd day of June, 2018 by and between Guided Therapeutics, Inc., (the "Company"), and GHS Investments, LLC (the "Investor"). Recitals A. The Investor wishes to purchase from the Company and the Company wishes to sell and issue to the Investor, upon the terms and conditions stated in this Agreement:
April 20, 2020	EX-10.15	SECURITIES PURCHASE AGREEMENT Exhibit 10.15 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of February 22, 2018, by and between Guided Therapeutics, Inc., a Delaware corporation, with its address at 5835 Peachtree Corners East, Suite D, Norcross, Georgia 30092 (the “Company”), and POWER UP LENDING GROUP LTD., a Virginia corporation, with its address at 111 Great Neck Road, Suite 21
April 20, 2020	EX-10.26	PROMISSORY NOTE Exhibit 10.26 PROMISSORY NOTE Original Issuance Date: September 6, 2018 Principal Amount: $50,000 THIS PROMISSORY NOTE is duly authorized and validly Note of Guided Therapeutics, Inc., a Delaware corporation, (the "Company"), having its principal place of business at 5835 Peachtree Corners East, Suite B, Norcross, Georgia 30092. FOR VALUE RECEIVED, the undersigned promises to pay to John Gould ("H
April 20, 2020	EX-10.31	PROMISSORY NOTE Exhibit 10.31 PROMISSORY NOTE Original Issuance Date: February 15,2019 Principal Amount: $50,000.00 THIS PROMISSORY NOTE is duly authorized and validly Note of Guided Therapeutics, Inc., a Delaware corporation, (the "Company"), having its principal place of business at 5835 Peachtree Corners East, Suite B, Norcross, Georgia 30092. FOR VALUE RECEIVED, the undersigned promises to pay to John W. Goul
April 20, 2020	EX-10.34	SECURITIES PURCHASE AGREEMENT Exhibit 10.34 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of May 15, 2019, by and between Guided Therapeutics, Inc., a Delaware corporation, with headquarters located at 5835 Peachtree Comers East, Suite B, Norcross, GA 30092, (the "Company") and ADAR ALEF, LLC, a New York limited liability company, with its address at 38 Olympia Lane, Monsey NY 109
April 20, 2020	EX-10.55	PROMISSORY NOTE Exhibit 10.55 Page 1 of 1 Howe File Number: 17-10826 PROMISSORY NOTE STATE OF GEORGIA COUNTY OF FOR AND IN CONSIDERATION OF the sum of Ten ($10.00) Dollar cash in hand, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, GUIDED THERAPEUTICS, INC., presently of 5835 Peachtree Corners East, STE B, Peachtree Comers, GA 30092, ("Promisor"), here
April 20, 2020	EX-3.4	Loan Agreement, dated as of July 1, 2019, by and between Guided Therapeutics, Inc. and Accilent Capital Management Inc. / Rev Royalty Trust Income and Growth Trust (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) Exhibit 3.4 Delaware The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF DESIGNATION OF “GUIDED THERAPEUTICS, INC.”, FILED IN THIS OFFICE ON THE THIRTY-FIRST DAY OF MARCH, A.D. 2020, AT 12:50 O`CLOCK P.M. A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORD
April 20, 2020	EX-4.33	COMMON STOCK PURCHASE WARRANT GUIDED THERAPEUTICS, INC. Exhibit 4.33 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
April 20, 2020	EX-10.56	EXCHANGE AGREEMENT Exhibit 10.56 EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (this "Agreement") is made and entered into effective as of the 16th day of January, 2020 by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the "Company") and the undersigned creditor of the Company (the "Creditor"). WHEREAS, the Creditor is the payee of certain obligations owed to the Creditor by the Company as set forth bel
April 20, 2020	EX-10.51	EXCHANGE AGREEMENT Exhibit 10.51 EXCHANGE AGREEMENT THE EXCHANGE GREEMENT (this "Agreement") is made and entered into effective as of the 30 day of December, 2019, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation (the "Company") and the undersigned creditor of the Company (the "Creditor"). WHEREAS, the Creditor is the payee of certain obligations owed to the Creditor by the Company as set forth on Ex
April 20, 2020	EX-10.27	PROMISSORY NOTE (Replaces deferred compensation of $207,110.86) Exhibit 10.27 PROMISSORY NOTE (Replaces deferred compensation of $207,110.86) $207,110.86 September 4, 2018 FOR VALUE RECEIVED, Guided Therapeutics, loc., a Delaware corporation (referred to hereinafter as "Maker" and "Company"), hereby promises to pay to Mark Faupel ("Holder") the principal sum of Two Hundred Seven Thousand, One Hundred Ten Dollars AND Eighty Six Cents ($207,110,86), plus accrued
April 20, 2020	EX-10.40	SECURITIES PURCHASE AGREEMENT Exhibit 10.40 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of December 17, 2019, by and between GUIDED THERAPEUTICS, INC., a Delaware corporation, with headquarters located at 5835 Peachtree Comers East, Suite D, Norcross, Georgia 30092 (the "Company"), and AUCTUS FUND, LLC, a Delaware limited liability company, with its address at 545 Boylston Stree
April 20, 2020	EX-4.30	COMMON STOCK PURCHASE WARRANT GUIDED THERAPEUTICS, INC. Exhibit 4.30 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
March 31, 2020	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2019 GUIDED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22179 (Commission File Number
March 9, 2020	10-Q	GTHP / Guided Therapeutics, Inc. 10-Q - Quarterly Report - GUIDED THERAPEUTICS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934 For the quarterly period ended September 30, 2019 Commission File No. 0-22179 GUIDED THERAPEUTICS, INC. (Exact Name of Registrant as Spe
February 11, 2020	10-Q	GTHP / Guided Therapeutics, Inc. 10-Q - Quarterly Report - GUIDED THERAPEUTICS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934 For the quarterly period ended June 30, 2019 Commission File No. 0-22179 GUIDED THERAPEUTICS, INC. (Exact Name of Registrant as Specifie
August 15, 2019	NT 10-Q	GTHP / Guided Therapeutics, Inc. NT 10-Q - - GUIDED THERAPEUTICS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 000-22179 (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR [ ] Form N-CSR For Period Ended: June 30, 2019 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form N-SAR For the Transition Period Ended: Nothing in the form shall be construed to imply that Commission has verified any information contained herein.
July 11, 2019	10-Q	GTHP / Guided Therapeutics, Inc. 10-Q - Quarterly Report - GUIDED THERAPEUTICS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934 For the quarterly period ended March 31, 2019 Commission File No. 0-22179 GUIDED THERAPEUTICS, INC. (Exact Name of Registrant as Specifi
May 15, 2019	NT 10-Q	GTHP / Guided Therapeutics, Inc. NT 10-Q GUIDED THERAPEUTICS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 000-22179 (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR [ ] Form N-CSR For Period Ended: March 31, 2019 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form N-SAR For the Transition Period Ended: Nothing in the form shall be construed to imply that Commission has verified any information contained herein.
May 8, 2019	10-K	GTHP / Guided Therapeutics, Inc. 10-K Annual Report FORM 10-K 10-K 1 gthp10k.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018. OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numb
April 3, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2019 (March 27, 2019) GUIDED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-22179 58-2029543 (State or other jurisdiction of incorpora
April 1, 2019	NT 10-K	GTHP / Guided Therapeutics, Inc. GUIDED THERAPEUTICS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 000-22179 (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR [ ] Form N-CSR For Period Ended: December 31, 2018 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form N-SAR For the Transition Period Ended: Nothing in the form shall be construed to imply that Commission has verified any information contained herein.
November 14, 2018	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2018 (November 7, 2018) GUIDED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-22179 58-2029543 (State or other jurisdiction of inc
November 14, 2018	EX-3	Amended and Restated Certificate of Incorporation, (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed November 15, 2018) Exhibit 3.1 Delaware Page 1 The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF “GUIDED THERAPEUTICS, INC.”, FILED IN THIS OFFICE ON THE SEVENTH DAY OF NOVEMBER, A.D. 2018, AT 8:31 O’CLOCK A.M. A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECO
November 14, 2018	10-Q	GTHP / Guided Therapeutics, Inc. GUIDED THERAPEUTICS, INC. (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934 For the quarterly period ended September 30, 2018 Commission File No. 0-22179 GUIDED THERAPEUTICS, INC. (Exact Name of Registrant as Spe
October 25, 2018	8-K	Submission of Matters to a Vote of Security Holders 8-K 1 gthp8k102518.htm GUIDED THERAPEUTICS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2018 (October 19, 2018) GUIDED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-2217
October 11, 2018	DEF 14A	2018 Stock Option Plan of the Registrant (incorporated by reference to Annex B of Definitive Proxy Statement filed October 11, 2018) SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ☐ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Solicitation Material Under Rule 14a-12 GUIDED THERAPEUTICS, INC.
September 28, 2018	PRE 14A	GTHP / Guided Therapeutics, Inc. GUIDED THERAPEUTICS, INC. SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Solicitation Material Under Rule 14a-12 GUIDED THERAPEUTICS, INC.
September 17, 2018	DEF 14A	GTHP / Guided Therapeutics, Inc. GUIDED THERAPEUTICS, INC. SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ☐ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Solicitation Material Under Rule 14a-12 GUIDED THERAPEUTICS, INC.
September 6, 2018	EX-3.1	GUIDED THERAPEUTICS, inc. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C2 CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE Delaware GENERAL CORPORATION LAW Exhibit 3.1 GUIDED THERAPEUTICS, inc. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C2 CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE Delaware GENERAL CORPORATION LAW The undersigned, Dr. Gene S. Cartwright, does hereby certify that: 1. He is the President and Chief Executive Officer of Guided Therapeutics, Inc., a Delaware corporation (the "Corporation").
September 6, 2018	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits 8-K 1 gthp8k9618.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2018 (August 31, 2018) GUIDED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other juris
September 6, 2018	EX-10.1	Exchange Agreements, dated as of August 31, 2018, by and between Guided Therapeutics, Inc. and Series C1 Preferred Stockholders in exchange for Series C2 Preferred Stock. (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K filed September 6, 2018) EX-10.1 3 ex10one.htm FORM OF EXCHANGE AGREEMENT Exhibit 10.1 SHARE EXCHANGE AGREEMENT THIS SHARE EXCHANGE AGREEMENT (this “Agreement”) is entered into as of the 31st day of August, 2018 by and among Guided Therapeutics, Inc., a Delaware corporation (the “Company”) and each of the shareholders of the Company identified on Schedule A hereto (each a “Shareholder,” and collectively, the “Shareholders
September 5, 2018	PRE 14A	GTHP / Guided Therapeutics, Inc. GUIDED THERAPEUTICS, INC. SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Solicitation Material Under Rule 14a-12 GUIDED THERAPEUTICS, INC.
August 14, 2018	10-Q	GTHP / Guided Therapeutics, Inc. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934 For the quarterly period ended June 30, 2018 Commission File No. 0-22179 GUIDED THERAPEUTICS, INC. (Exact Name of Registrant as Specifie
July 9, 2018	CORRESP	GTHP / Guided Therapeutics, Inc. CORRESP July 9, 2018 United States Securities and Exchange Commission Attn: Tim Buchmiller Division of Corporation Finance 100 F Street, N.
June 14, 2018	EX-10.45	EQUITY FINANCING AGREEMENT EX-10.45 3 gthpex1045.htm EQUITY FINANCING AGREEMENT Exhibit 10.45 EQUITY FINANCING AGREEMENT This EQUITY FINANCING AGREEMENT (the “Agreement”), dated as of March 1, 2018 (the “Execution Date”), is entered into by and between Guided Therapeutics, Inc., a Delaware corporation with its principal executive office at 5835 Peachtree Corners East, Norcross, Georgia 30092 (the “Company”),and GHS Investme
June 14, 2018	S-1	GTHP / Guided Therapeutics, Inc. REGISTRATION STATEMENT S-1 1 gthps1.htm REGISTRATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Guided Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 3845 58-2029543 (State of Incorporation) (Primary Standard Industrial Classification Number) (IRS Employer Identification Number) 5835
June 14, 2018	EX-10.46	REGISTRATION RIGHTS AGREEMENT EX-10.46 4 gthpex1046.htm FORM OF REGISTRATION RIGHTS AGREEMENT Exhibit 10.46 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (the “Agreement”), dated as of March 8, 2018 (the “Execution Date”), is entered into by and between Guided Therapeutics, Inc., a Delaware corporation with its principal executive office at 5835 Peachtree Corners East, Suite D, Norcross, GA 30092 (the “Compa

GTHP / Guided Therapeutics, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)